Lorlatinib vs chemoradiation for ALK-positive lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares a newer targeted pill (lorlatinib) with standard chemoradiation (chemo plus radiation) for people with stage III ALK-positive lung adenocarcinoma. The goal is to see if lorlatinib alone works better than standard treatment and causes fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be a type of lung cancer called adenocarcinoma that tests positive for the ALK gene change (your doctor can check this with a special test).
- Your cancer must be stage III, meaning it has spread to nearby tissue or lymph nodes but cannot be removed with surgery.
- You must not have already had treatment with an ALK inhibitor (like crizotinib or alectinib) or radiation to the chest.
- You need to be 18 years or older and in generally good health (able to care for yourself and walk around).
- You must have at least one tumor that can be measured on scans, and your blood counts and organ function need to be within a safe range.
- You cannot have an active infection, a history of lung scarring (interstitial lung disease), or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking lorlatinib before surgery can shrink or control early-stage lung cancer that has a specific genetic change (ALK). It aims to improve surgical outcomes and reduce the chance of the cancer coming back.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Hear when a new Neoadjuvant Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.